FDA approves Liquidia's inhaled hypertension drug in two settings
The FDA approved Liquidia’s treprostinil program for two related kinds of high blood pressure, turning up the heat on rival United Therapeutics and its Tyvaso franchise. Treprostinil, now branded as Yutrepia, is indicated for patients ...
The FDA approved Liquidia’s treprostinil program for two related kinds of high blood pressure, turning up the heat on rival United Therapeutics and its Tyvaso franchise.
Treprostinil, now branded as Yutrepia, is indicated for patients ...
